DBV Technologies (DBVT) Competitors $9.46 -0.03 (-0.31%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DBVT vs. LENZ, ZYME, SYRE, UPB, STOK, VERV, PRAX, VALN, CRMD, and MLYSShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include LENZ Therapeutics (LENZ), Zymeworks (ZYME), Spyre Therapeutics (SYRE), Upstream Bio (UPB), Stoke Therapeutics (STOK), Verve Therapeutics (VERV), Praxis Precision Medicines (PRAX), Valneva (VALN), CorMedix (CRMD), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. Its Competitors LENZ Therapeutics Zymeworks Spyre Therapeutics Upstream Bio Stoke Therapeutics Verve Therapeutics Praxis Precision Medicines Valneva CorMedix Mineralys Therapeutics LENZ Therapeutics (NASDAQ:LENZ) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment. Which has higher valuation & earnings, LENZ or DBVT? LENZ Therapeutics has higher earnings, but lower revenue than DBV Technologies. LENZ Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$49.77M-$1.90-20.11DBV Technologies$4.15M62.30-$113.92M-$4.77-1.98 Do analysts prefer LENZ or DBVT? LENZ Therapeutics currently has a consensus price target of $49.60, indicating a potential upside of 29.84%. DBV Technologies has a consensus price target of $14.75, indicating a potential upside of 56.25%. Given DBV Technologies' higher possible upside, analysts clearly believe DBV Technologies is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has more risk & volatility, LENZ or DBVT? LENZ Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.58, meaning that its stock price is 158% less volatile than the S&P 500. Do institutionals & insiders believe in LENZ or DBVT? 54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by company insiders. Comparatively, 1.4% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is LENZ or DBVT more profitable? LENZ Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,220.49%. LENZ Therapeutics' return on equity of -25.63% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -25.63% -24.43% DBV Technologies -3,220.49%-287.15%-138.83% Does the media favor LENZ or DBVT? In the previous week, LENZ Therapeutics had 2 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for LENZ Therapeutics and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.47 beat LENZ Therapeutics' score of 0.85 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLENZ Therapeutics beats DBV Technologies on 10 of the 15 factors compared between the two stocks. Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$259.93M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.01%P/E Ratio-1.987.3622.5622.49Price / Sales62.30398.26463.84113.07Price / CashN/A44.6737.7359.36Price / Book3.008.0910.046.68Net Income-$113.92M-$54.08M$3.27B$265.59M7 Day Performance-1.05%2.25%3.17%3.42%1 Month Performance-4.21%3.41%4.34%1.09%1 Year Performance117.01%18.61%44.12%23.84% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies3.3996 of 5 stars$9.44-0.5%$14.75+56.3%+111.9%$259.93M$4.15M-1.9880Positive NewsGap DownLENZLENZ Therapeutics1.8118 of 5 stars$38.77+2.4%$49.60+27.9%+69.9%$1.08BN/A-20.41110ZYMEZymeworks0.0467 of 5 stars$14.05-2.2%N/AN/A$1.08B$76.30M-14.48460SYRESpyre Therapeutics3.085 of 5 stars$16.94-0.1%$53.40+215.2%-38.4%$1.02B$890K-4.9873News CoveragePositive NewsUPBUpstream Bio2.3105 of 5 stars$18.02-4.8%$56.50+213.5%N/A$1.02B$2.37M0.0038STOKStoke Therapeutics4.4774 of 5 stars$18.51+1.6%$25.57+38.1%+39.1%$997.86M$36.56M21.78100VERVVerve Therapeutics2.7658 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110PRAXPraxis Precision Medicines1.7013 of 5 stars$46.63-1.0%$85.88+84.2%-12.3%$990.84M$8.55M-3.79110VALNValneva2.0786 of 5 stars$12.14+5.3%$15.50+27.7%+14.5%$981.14M$183.52M-12.39700Analyst ForecastGap UpCRMDCorMedix2.7102 of 5 stars$13.10+1.3%$16.71+27.6%+129.2%$965.21M$43.47M17.4730Positive NewsMLYSMineralys Therapeutics3.2601 of 5 stars$15.34+5.6%$32.25+110.2%+24.7%$962.61MN/A-4.3128Positive NewsAnalyst Forecast Related Companies and Tools Related Companies LENZ Therapeutics Alternatives Zymeworks Alternatives Spyre Therapeutics Alternatives Upstream Bio Alternatives Stoke Therapeutics Alternatives Verve Therapeutics Alternatives Praxis Precision Medicines Alternatives Valneva Alternatives CorMedix Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DBVT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access